2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Margetuximab

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.

For research use only. We do not sell to patients.

CAS No. : 1350624-75-7

Size Price Stock Quantity
1 mg USD 280 In-stock
5 mg USD 680 In-stock
10 mg USD 1100 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Margetuximab Related Antibodies

Top Publications Citing Use of Products

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Chimeric
IC50 & Target

EC50: 39.33 ng/mL (HER2)[1]
In Vitro

Margetuximab (MGAH22) enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Margetuximab Related Antibodies

Cell Proliferation Assay

Cell Line: JIMT-1, MCF-7, ZR-75-1, SKBR-3, HT-29, SW750 and N87[1]
Concentration: 0.001-1000 ng/mL
Incubation Time: 6 days
Result: Enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant.
In Vivo

Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 - 37 in mice model[1].
Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release[1].
Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile[1].
Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys[1].

Male, IV (50 mg/kg) Female, IV (50 mg/kg)
Cmax (mg/mL) 1.62 ± 0.10 1.70 ± 0.14
AUC0-￥ (mg·hour/mL) 294.1 ± 53.2 314.2 ± 31.3
T1/2β (days) 9.3 ± 1.8 9.7 ± 1.1
Clearance (mL/hour) 0.43 ± 0.07 0.40 ± 0.04
VSS (mL) 132 ± 2 127 ± 8

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Margetuximab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Margetuximab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Margetuximab1350624-75-7EGFREpidermal growth factor receptorErbB-1HER1HER2JIMT-1Cynomolgus monkeysAnticancerMetastatic HER2-positive breast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Margetuximab
Cat. No.:
HY-P99030
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.